1-(3-Chloropropyl)piperazinedihydrochloridehemihydrate

Catalog No. :
ACTITU914
CAS No. :
34782-06-4
Molecular Formula :
C7H19Cl3N2O
Molecular Weight :
253.60

IUPAC Name:1-(3-Chloropropyl)piperazinedihydrochloridehemihydrate

1-(3-Chloropropyl)piperazinedihydrochloridehemihydrate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg95%$70.00Login to see priceInquiryInquiry
10mg95%$96.00Login to see priceInquiryInquiry
50mg95%$156.00Login to see priceInquiryInquiry
100mg95%$221.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(3-Chloropropyl)piperazinedihydrochloridehemihydrate
IUPAC Name1-(3-Chloropropyl)piperazinedihydrochloridehemihydrate
MDL No.MFCD00150090
Molecular FormulaC7H19Cl3N2O
Molecular Weight253.60
SMILESO.Cl.Cl.ClCCCN1CCNCC1
InChI KeySZJBSCDUZKUYQE-UHFFFAOYSA-N
Synonym1-(3-chloropropyl)piperazine dihydrochloride monohydrate;1-(3-Chloropropyl)piperazine2HClhemihydrate;1-(3-Chloropropyl)piperazine dihydrochloride hemihydrate 95%;1-(3-Chloropropyl)piperazine dihydrochloride monohydrate,98%;1-(3-Chloropropyl)Piperazine 2hcl;1-(3-Chloropropyl)piperazine 2HCl.5H20;1-(3-Chloroprop-1-yl)piperazine dihydrochloride hemihydrate 95%;1-(3-Chloroprop-1-yl)piperazine dihydrochloride hemihydrate
CAS No.34782-06-4

Synthetic Route by SureRoute

1. ACTITU914 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBIRA687 route compound structure diagram
    ACBIRA687165530-45-0 In Stock
  2. Then
  3. ACTITU914 route product structure diagram
    ACTITU91434782-06-4
Inquiry

2. ACTITU914 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTITU914 route product structure diagram
    ACTITU91434782-06-4
Inquiry

Comments (0)